CN1674902A - 新晶型的加替沙星 - Google Patents

新晶型的加替沙星 Download PDF

Info

Publication number
CN1674902A
CN1674902A CNA038193094A CN03819309A CN1674902A CN 1674902 A CN1674902 A CN 1674902A CN A038193094 A CNA038193094 A CN A038193094A CN 03819309 A CN03819309 A CN 03819309A CN 1674902 A CN1674902 A CN 1674902A
Authority
CN
China
Prior art keywords
gatifloxacin
crystalline form
solution
hours
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038193094A
Other languages
English (en)
Chinese (zh)
Inventor
V·尼丹-希尔德谢姆
S·维泽尔
G·斯特林鲍姆
E·阿米尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN1674902A publication Critical patent/CN1674902A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA038193094A 2002-06-14 2003-06-16 新晶型的加替沙星 Pending CN1674902A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38909302P 2002-06-14 2002-06-14
US60/389,093 2002-06-14
US42333802P 2002-11-01 2002-11-01
US60/423,338 2002-11-01

Publications (1)

Publication Number Publication Date
CN1674902A true CN1674902A (zh) 2005-09-28

Family

ID=29740100

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038193094A Pending CN1674902A (zh) 2002-06-14 2003-06-16 新晶型的加替沙星

Country Status (8)

Country Link
US (2) US7411067B2 (enExample)
EP (1) EP1471911A1 (enExample)
JP (1) JP2005532364A (enExample)
CN (1) CN1674902A (enExample)
AU (1) AU2003243615A1 (enExample)
CA (1) CA2489377A1 (enExample)
IL (1) IL165690A0 (enExample)
WO (1) WO2003105851A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118546A1 (en) * 2004-06-04 2005-12-15 Matrix Laboratories Ltd Novel crystalline forms of gatifloxacin
CA2621616A1 (en) * 2007-02-19 2008-08-19 Alcon Research, Ltd. Topical gatifloxacin formulations
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0629621B1 (en) 1992-01-31 2001-10-24 Chugai Seiyaku Kabushiki Kaisha Crystal of quinolonecarboxylic acid derivative hydrate
JP3449658B2 (ja) 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
US6413969B1 (en) 2000-09-13 2002-07-02 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
CA2481308A1 (en) 2002-04-08 2003-10-23 Dr. Reddy's Laboratories Limited Anhydrous crystalline forms i and ii of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl) 4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (gatifloxacin)

Also Published As

Publication number Publication date
EP1471911A1 (en) 2004-11-03
AU2003243615A1 (en) 2003-12-31
JP2005532364A (ja) 2005-10-27
IL165690A0 (en) 2006-01-15
US7411067B2 (en) 2008-08-12
WO2003105851A1 (en) 2003-12-24
US20080269488A1 (en) 2008-10-30
US20040038988A1 (en) 2004-02-26
CA2489377A1 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
CN1105705C (zh) 一种特定物理形态的杂环酰胺衍生物的制备方法
CN1298322C (zh) 卡维地洛的结晶固体及其制备方法
CN1681802A (zh) 兰索拉唑多晶型和其制备方法
CN101022812A (zh) 固体和晶体伊班膦酸钠及其制备方法
JP2007514000A (ja) テガセロッド塩基及びその塩の多形現象形
CN1633439A (zh) 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
WO2007062147A1 (en) Crystal forms of cinacalcet hci and processes for their preparation
EP2103612A1 (en) Crystalline forms of palonosetron hydrochloride
JP2005534633A (ja) ガチフロキサシンの新規結晶形
US20080269488A1 (en) Novel crystalline forms of gatifloxacin
WO2006108151A1 (en) Crystalline forms of pregabalin
US7396839B2 (en) Crystalline forms of gatifloxacin
US20060258677A1 (en) Novel crystalline forms of gatifloxacin and processes for preparation
JP2006511618A (ja) ガチフロキサシンの結晶形態および調製の方法
MX2007002113A (es) Formas polimorfas de maleato de tegaserod.
US20090105490A1 (en) Polymorphic forms of ramelteon and processes for preparation thereof
CN1688310A (zh) 加替沙星的新晶型
KR20070088507A (ko) 카베딜올의 결정질 형태 및 이것의 제조 방법
WO2023137060A1 (en) Solid state forms of rucaparib tosylate
WO2025141465A1 (en) Solid state forms of zipalertinib hydrochloride and process for preparation thereof
CN1694884A (zh) Ⅰ晶型、ⅱ晶型、ⅲ晶型泛昔洛韦及其制备方法
WO2008130630A2 (en) Polymorphic form of rimonabant hydrochloride and processes for preparation thereof
JP2007513867A (ja) モダフィニル組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication